S.T. Stent

S.T. Stent is developing a removable stent for use after Functional Endoscopic Sinus Surgery (FESS) to keep the sinus cavity open for almost a month, long enough for the tissue to heal.

The Product & Advantages

The stent, for insertion after FESS, keeps the sinus cavity open up to 28 days, long enough for the sinus tissue to heal. The stent improves patient outcomes and reduces the probability of revision surgeries.

  • Adapts to anatomy and does not migrate
  • Provides strong, stable support of sinus walls
  • Made of biocompatible materials
  • Does not irritate tissue, comfortable for patient
  • Easily removed in the doctor’s office without anesthesia

The Team


S.T. Stent CEO Jospeh Flomenblit (center) with QA Manager Lena Schlossberg (right) at the 5th Annual Trendlines Company Showcase networking session.

  • Joseph Flomenblit, PhD, CEO: More than 25 years’ experience developing stents; international expert in nitinol alloy; scientific advisor for Boston Scientific, J&J, Stryker, Velocimed, Rafael; founder, Litana; inventor, more than 60 patents; PhD, physics
  • Gregory Frenklech, Chief Engineer: International expert in inventive problem-solving theory (TRIZ); 15 years’ experience in medical device industry; former head of mechanical design, Medinol; consults to medical device start-ups; MSc, engineering
  • Lena Shlossberg, QA Manager: Medical research experience at Sheba Medical Center; regulatory experience at Mediwound; MSc, biology
  • Zeev Bronfeld, Chairman: Trendlines’ board of directors since 2007; co-founder, CEO, and director, Bio-Cell; director, D.N.A. Biomedical Solutions Industries; chairman, Protalix
  • Prof. Gady Har-El, MD, Scientific Adviser: Chairman, Otolaryngology-Head and Neck Surgery, Lenox Hill Hospital, New York
  • Prof. Eitan Yaniv, MD, Scientific Adviser: Head of Nose and Sinus Institute, Rabin Medical Center, Israel; leading surgeon in the ENT field

Trendlines’ directors: Zeev Bronfeld, Todd Dollinger


Founded: November 2013
Stage: Business development
Investors: The Trendlines Group, private investor
IP: One issued patent (United States), two pending (Canada, Europe, Japan, China)

Recent Developments

  • Raised $1.1 million
  • Preparing manufacturing capabilities for first approved product for American and Israeli market
  • Preparing first U.S. clinical cases (Lenox Hill Hospital, NY)
  • Preparing for sales in Israel


  • December 2017: FDA clearance
  • June 2017: 30-patient clinical trial
  • March 2017: Filed 510(k)
  • December 2016: successful FIH, including stent removal after four weeks, three-month follow-up; excellent therapeutic results

Background & Market

Chronic sinusitis is constant inflammation of the sinus caused by infection or allergy and characterized by facial pain and pressure, nasal congestion, and headaches. When drug treatments fail, Functional Endoscopic Sinus Surgery (FESS) is performed to improve airflow within the nose and sinuses, improve drainage, and eliminate diseased tissue.

Unfortunately, up to 30% of sinus surgeries fail due to scarring and recurrent inflammation that closes the nasal openings and requires revision sinus surgery (RSNA RadioGraphics). According to Intersect ENT, the estimated sinus stent market opportunity exceeds $3 billion in the United States

There are more than 1 million FESS procedures performed annually in the United States and Europe.


CEO Joseph Flomenblit presents at Trendlines 5th Annual Showcase.


Joseph Flomenblit, Ph.D., CEO

STStent logo

Font Resize